E nforced myocardial neovascularization offers an attractive potential opportunity for rectifying insufficient perfusion of the heart muscle and for ameliorating its pathological sequela. However, despite promising preclinical studies, 1, 2 it is still debated whether therapeutic neovascularization is at all feasible, let alone during the end stage of ischemic heart disease (IHD), where substantial alterations of cardiac interstitial tissue, primarily extensive fibrosis may hamper the angiogenic response. Here, we examined the potential utility of vascular endothelial growth factor (VEGF)-mediated myocardial neovascularization during progressive stages of IHD, including its end stage.
Cardiac remodeling is a broad term describing the overall functional and structural changes of the myocardium in response to chronic overload or injury. [3] [4] [5] Remodeling is an adaptive process including cellular and interstitial alterations within the cardiac tissue enabling the heart to withstand increased mechanical stress. Unfortunately, however, at later disease stages this beneficial adaptive process almost always becomes maladaptive and a prognostic determinant of heart failure. 6 Correspondingly, therapeutic approaches to reverse maladaptive remodeling are currently considered a prime clinical goal. Studies with human patients 7 and in animal models 8 have shown that at early stages of IHD, characterized by cardiac dysfunction without an extensive myocardial death, remodeling can be fully reversed. It is not known, however, whether ability to enforce reversal is preserved at late stages of disease. 9, 10 Answering this eminent question has been hampered by the lack of a suitable animal model simulating progressive, consecutive stage of cardiac remodeling.
Here we used a unique transgenic mouse system developed in our laboratory for conditional induction of IHD, where progressive reduction in cardiac function leads to a substantial cardiac remodeling. The system is based on myocardiumspecific induction of a VEGF-sequestering soluble receptor and a resultant vascular deficit. Importantly, ensuing cellular hypoxia is tunable to a level at which large cohorts of cardiomyocytes are driven to enter a hibernation mode. A resultant increase in myocardial dysfunction eventually leads to left ventricular (LV) volume overload. 11 Here, the system was harnessed for studying successive stages in myocardial remodeling by examining the progression of its hallmarks, namely, LV enlargement, cardiomyocyte hypertrophy, and interstitial fibrosis. Importantly, terminating the VEGF blockade in this system results in rapid VEGF-driven neovascularization, 11 thus providing a unique opportunity to determine whether the potential for VEGF-induced neovascularization is preserved even at late stages of IHD progression. We show that VEGF-induced myocardial neovascularization is possible even at the end stage of IHD and, moreover, that myocardial function can be rescued. Further, these results have provided us with the opportunity to determine whether remodeling reversal will follow, a question greatly impacting the issue of whether a contemplated proangiogenic therapy might also be beneficial at late stages where remodeling reversal becomes a critical issue.
Methods

Transgenic Mice and Conditional Modulations of VEGF Signaling
A bitransgenic system for organ-specific, tetracycline-regulated transgene expression was used. Heart-specific induction was achieved by using a transgenic driver line in which tetracycline transactivator expression is driven by a myosin heavy chain (MyHC) heartspecific promoter. 12 The tetracycline-regulated soluble VEGF receptor 1 (sVEGFR1) transgenic line encodes a tetracycline-inducible protein composed of an IgG1-Fc tail fused to the extracellular domain of VEGFR1 (corresponding to amino acid residues 1-631 of human VEGFR1 containing the ligand-binding domain but lacking the transmembrane and cytoplasmic domains). Induction of sVEGFR1 in double-transgenic (dTg) mice was accomplished by tetracycline withdrawal and the termination of sVEGFR1 by tetracycline addition (0.5-mg/mL tetracycline and 3% sucrose in the drinking water). Animals were euthanized using 200-mg/kg pentobarbital IP, followed by removal of the heart. All animal experiments conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, and were done under approval of the Hebrew University ethics committee (approval No. MD-10127064).
Immunohistochemistry
Paraffin sections (5 μm) were used, and antigen was retrieved by microwaving at 92°C in a citrate buffer (pH 6; Zymed Laboratories) for 20 minutes. Apoptosis was determined by using both a terminal deoxynucleotidyl transferase dUTP nick-end labeling assay and immunostaining for activated caspase-3 (Cell Signaling). Endothelial cells were visualized by using Bandeiraea simplicifolia isolectin B4 staining. Antibodies were antiperiostin goat polyclonal antibody (BAF2955 by R&D), antidiscoidin domain receptor 2 rabbit polyclonal antibody (sc-8989 by Santa Cruz), and anti-smooth muscle actin mouse monoclonal antibody (M0851 by DAKO).
Periostin Protein Analysis
Whole-heart protein extracts were prepared. For immunoprecipitation, extracts were incubated for 3 hours with antiperiostin rat monoclonal antibody (MAB3548 by R&D) than subjected to protein A and eluted by centrifugation. For Western blotting analysis, proteins were resolved on a 10% SDS-PAGE under reducing conditions and transferred to a minipore membrane, and incubated with antiperiostin goat polyclonal antibody (BAF2955 by R&D) and subsequently, with HRP-conjugated anti-goat IgG. Immunoreactivity was revealed by enhanced chemiluminescence using an ECL kit (Amersham Pharmacia Biotech, Les Ulis, France). Serum periostin was detected using Western blotting by loading 2 μL of serum diluted in 18 μL of sample buffer. In situ hybridization on paraffin sections was performed as described previously. 13 
RNA Analysis
For real-time polymerase chain reaction analysis, cDNA was generated from 5 mg of total RNA by using Verso cDNA kit (Thermo Scientific) and the respective primers. Samples were normalized according to L19 mRNA levels by SYBR green real-time polymerase chain reaction.
Echocardiography
Transthoracic echocardiography was performed on shallow anesthetized mice (ketamine and xylazine, 200 mg/kg IM and 10 mg/kg IP). More details are available in the online-only Data Supplement.
Statistical Analysis
Numerical data are the mean±SE. Statistical significance was determined by using Student t test.
Results
A Conditional Transgenic System for Generating Progressive Degrees of Hypoperfused Heart and Cardiomyocyte Dysfunction
We wished to examine an experimental system in which heart remodeling develops at a slow, progressive pace, and thereby allowing a gradual, stepwise development of its individual cellular and molecular components. To this end, we harnessed the system we developed previously for generating a hypoperfused heart via conditional blockade of cardiac VEGF. The system is based on our findings that VEGF is indispensable for adjusting the cardiac microvasculature to match dynamic changes in oxygen supply and demand. 11 Briefly, a tetracycline-regulated VEGF decoy receptor (sVEGFR1) was conditionally induced in the heart using a cardiomyocyte-specific promoter driving expression of a transactivator protein ( Figure 1A ; Methods section). sVEGFR1, which binds both monomeric and dimeric VEGF, 14 is induced at a large molar excess over that of endogenous VEGF ( Figure I in the onlineonly Data Supplement), thereby assuring its full sequestration and complete inhibition of VEGF signaling. When applied at an early postnatal timing, induction of sVEGFR1 leads to a progressive microvascular deficit, the magnitude of which is determined by the duration of VEGF blockade ( Figure 1B ). This reduction in microvascular density (MVD) resulted in a progressive reduction in cardiomyocyte contractile function as monitored by echocardiography and evidenced by a reduced fractional shortening ( Figure 1C ).
VEGF blockade was maintained for up to 32 weeks, during this period a progressively deteriorating contractile function led to increased volume overload and a resultant cardiac remodeling (see below). Apoptosis of both cardiomyocytes and endothelial cells was increased in the VEGF-arrested (dTg) heart as evident by immunohistochemistry of cleaved caspase-3 after 3, 12, and 32 weeks from the onset of sVEGFR1 induction ( Figure  II in the online-only Data Supplement). In agreement with previous reports, 15 control mice also showed age-related increase in cardiomyocyte apoptosis. This increase was, however, faster in dTg mice, reaching maximum levels of cardiomyocyte apoptosis already after 12 weeks. After 32 weeks, no additional July 2012 cardiomyocyte apoptosis was evident in dTg mice compared with their littermate controls. In contrast, apoptosis of endothelial cells was increased in dTg mice at all stages examined, reflecting an indispensable role of VEGF in vascular homeostasis. This experiment thus confirms that inflicted endothelial cell apoptosis accelerates the previously reported natural, slow cardiomyocyte turnover rate.
Different Attributes of Remodeling Develop in a Stepwise Fashion Corresponding to Gradual Reduction in Cardiac Function
The ability to inflict myocardial dysfunction in a progressive manner provided a unique opportunity to determine the order of appearance and kinetics of the different attributes of remodeling. LV enlargement, accompanied by thinning of the LV wall (eg, Figure 2B ), developed early and with gradual and only modest increase in LV size at later stages ( Figure 1D ). In fact, LV enlargement was evident as early as 5 weeks from onset of VEGF blockade (Figure 2A) , and preceded the development of cardiomyocyte hypertrophy ( Figure 1E and 1F). To visualize fibrosis and determine its levels at progressive stages of remodeling, Masson trichrome collagen staining was used, and the relative myocardial area occupied by collagens was quantified. Consistent with previous studies, 16 fibrosis was found to increase with age in control animals, ranging from 0.2% at 3 weeks to 10.4% at 32 weeks ( Figure 1G and 1H). mice. E, Cardiomyocyte area was measured from hematoxylin and eosin-stained sections using ImageJ software, and was standardized to littermate controls. n=5 to 12 mice and 25 to 30 cardiomyocytes were measured for each section. F, Heart-to-body weight ratio n=7 to 13 mice. G and H, Representative images of heart sections stained with Masson trichrome reagent in which nuclei are colored in black, cytoplasm and muscle in red, and collagen in blue. Percent fibrosis was calculated as the collagen stain area relative to the total myocardial area using NIS-Elements image analysis software. n=5 to 12 mice and 3 to 5 HPF were analyzed for each mouse. I, Twelve control (diamonds) and 12 dTg (squares) mice were followed for 11 months for unprovoked deaths. Within the experiment time frame, 67% of the dTg mice died and none of the control mice. Presented are the results of 1 experiment of 3 conducted, with similar results. J, Schematic illustration of stepwise development of 3 hallmarks of remodeling (LV enlargement, hypertrophy, and fibrosis; text). *P<0.05, **P<0.001.
Relative to controls, hearts undergoing remodeling showed an elevated level of fibrosis already at 5 weeks post-sVEGFR1 induction (8.2% versus 4.7% in controls). Interestingly, although further increase in fibrosis was minimal during the following 15 weeks, it was dramatically increased at 32 weeks (33.5% versus 10.4% in controls). There was a clear temporal correlation between this later increase in fibrosis and mortality: although none of the transgenic animals died before 30 weeks from induction, a rapid decline in survival occurred thereafter, and only about 30% of mice survived to the end of the experiment at 44 weeks ( Figure 1I ). Based on these results, the overall remodeling process in our system was divided into 3 consecutive stages termed the early stage (characterized by ventricular dilatation and mild fibrosis), late stage (distinguished by addition of hypertrophy), and end stage (characterized by severe fibrosis associated with mortality; Figure 1J ).
sVEGFR1 Induction in the Adult Heart Results in Reversible Cardiomyocyte Dysfunction and Myocardial Fibrosis
To validate the relevance of the model system for IHD, we extended a similar analysis to the adult myocardium. VEGF blockade was initiated at 2 months of age, and the vasculature, LV function, and remodeling were examined up to the age of 6 months. Results clearly showed that the apparent impairment of vascular homeostasis in the mature myocardium led to similar heart remodeling phenotypes as those shown for the early Figure 2 . Remodeling is fully reversible by vascular endothelial growth factor receptor (VEGF)-driven neovascularization during the remodeling early and late stages but not during its end stage. A, End diastolic left ventricular (LV) diameter was measured by M-mode echocardiography. Soluble VEGF receptor 1 (sVEGFR1) was induced for 5, 12, 20, and 32 weeks followed by either 3 additional weeks of induction (ON) or 3 weeks of deinduction (ON>OFF). Each column represents the mean and SE of 4 to 6 mice. B, Axial sections at the level of the papillary muscle stained with hematoxylin and eosin (H&E), of control, double-transgenic (dTg) after 5 or 32 weeks of induction (ON) and 3 additional weeks of deinduction (ON>OFF). C, Cardiomyocyte areas were measured as described above These results, not only demonstrate the dependence on VEGF for maintaining cardiac vascular homeostasis, but also the relevance of the system for modeling adult onset IHD.
VEGF-Induced Neovascularization and Rescue of Contractile Function Are Feasible Even at the End Stage of IHD
A useful, inherent property of the experimental system is the option of examining phenotype reversibility after termination of the VEGF blockade (Methods). We have previously shown that terminating the VEGF blockade at time points corresponding to the early stage of remodeling results in rapid revascularization, culminating in full regain of normal MVD and a resultant complete rescue of contractile function within 1 week of sVEGFR1 deinduction. 11 As depicted in Figure 1J , we defined an end stage in our model characterized by further deterioration of cardiac function, massive fibrosis (reaching >30% of myocardial areas), and when mortality is first observed. To determine whether neovascularization and resultant restoration of cardiac function are still possible at this stage, the VEGF blockade was terminated at 32 weeks from onset to resume VEGF signaling. As shown in Figure 3A , by 3 weeks from sVEGFR1 deinduction, normal MVD in myocardial muscle tissue was fully regained. As a result, hibernating, dysfunctional cardiomyocytes were also rescued, evident by improvement of fractional shortening already after 2 weeks and almost reaching control levels by 3 weeks from deinduction ( Figure 3B ). These results demonstrate the remarkable capacity of viable, dysfunctional cardiomyocytes to be rescued even after months and at a time point proximal to fatal heart failure.
Remodeling Is Fully Reversible by VEGF-Driven Neovascularization During Remodeling Early and Late Stages
The ability to restore normal MVD and rescue contractile function has provided us with the opportunity to examine to what extent remodeling continues to be reversible as the process further progresses. To this end, VEGF blockade was terminated at different times from its onset (on>off mode), corresponding to the early stage (deinduced after 5 weeks), late stage (deinduced after 8, 12, or 20 weeks), and end stage (deinduction after 32 weeks) of remodeling. Full regain of normal MVD and rescue of contractile function (not shown) at the early remodeling stage led to reversal, as evidenced by a decrease in LV diameter (Figure 2A and 2B) . Similarly, at the late stage of remodeling, both LV enlargement and hypertrophy were fully reversed by restoring normal cardiac function within 3 weeks of deinduction ( Figure 2 ). As anticipated when considering the long half-life of collagens, fibrosis (measured by collagen staining) was not resolved at this time point but was resolved after 2 months of deinduction ( Figure IV 
A Point of No Return for Reversing Heart Remodeling
Despite restoring vascular and cardiomyocyte function, however, ≈40% of the surviving mice after sVEGFR1 deinduction died within 3 weeks (data not shown), suggesting a failure to rescue some other vital parameter. To determine whether remodeling is reversible at this end stage, we first measured LV size, and found it to be unaffected by revascularization Figure 3 . Vascular endothelial growth factor receptor (VEGF)-induced neovascularization and rescue of contractile function are feasible even at the end stage of ischemic heart disease. A, Microvascular density (MVD) was determined as described above. Values shown were adjusted to the myocardial area occupied by nonfibrotic tissue (fibrotic areas were determined as described in Figure 1 ). Soluble VEGF receptor 1 (sVEGFR1) was induced immediately after birth, and where indicated (ON>OFF) was deinduced after 32 weeks. All mice were analyzed at 35 weeks of age. Control 285 (n=5 mice; 14 high-power field [HPF] counted for lectin, 25 for Masson trichrome), doubletransgenic (dTg) ON 152 (n=5, 15, 25) , and dTg ON>OFF 253 (n=8, 23, 21) . B, Fractional shortening (SF) was measured for control and dTg mice after 32 weeks of induction. Then, sVEGFR1 was deinduced, and subsequent measurements were taken after 2 and 3 weeks (dTg ON>OFF; n=5). SF was also determined for 2 dTg mice without deinduction (dTg ON). *P<0.05, **P<0.001. (Figure 2A and 2B) . Likewise, hypertrophy was also irreversible at this stage ( Figure 2C and 2D ).
Irreversible Cardiac Hypertrophy Is Associated With an Irreversible Cardiac Myosin Isoform Shift
During heart failure progression, loss of the ability to generate effective shortening velocity is associated with a myosin isoform shift from the fast-contracting MyHCα to the slowcontracting MyHCβ. 17 We have examined the expression levels of both MyHCα and MyHCβ at time points representing and distinguishing reversible (12-week induction) and irreversible remodeling (32-week induction). As shown in Figure 4 , expression of MyHCβ was markedly upregulated in remodeled hearts at both time points. MyHCα was unchanged after 12 weeks, and was significantly reduced after 32 weeks of induction, thus verifying an isoform shift with progressive increase in the relative expression of MyHCβ compared with MyHCα. When attempting reversal, MyHCβ expression was reduced back to base, only when the reversal was attempted before the point of no return. When attempting reversal after 32 weeks, this isoform shift was only partly reversed, signifying a loss of the ability to restore normal myofilament composition.
Accumulation of Collagens During Progressive Remodeling Correlates With Increased Tissue Inhibitor of Metalloproteinase 1
As shown above, the remodeling point of no return is characterized by a critical level of fibrosis. To uncover possible players mediating the apparent gradual accumulation of collagens, we examined collagen I and collagen III production at time points representing and distinguishing reversible and irreversible remodeling. Expression of collagen I and collagen III mRNA was significantly upregulated at both time points ( Figure 5A ). This was reflected in progressive increase in collagen I deposition ( Figure 5B and 5C ). Tissue inhibitor of metalloproteinase 1 (TIMP1), a potent inhibitor of collagenases and a protein known to mediate cardiac fibrosis, 18 was markedly upregulated both at the RNA and protein levels, suggesting that collagen accumulation is, at least partly due to decreased degradation ( Figure 5D and 5E). After entering the phase of irreversible remodeling, TIMP1 could also be detected in the serum ( Figure 5F ). This finding is in agreement with previous studies of human heart failure patients, 19, 20 and may provide a rationale for using TIMP1 as a serum biomarker indicative of a state of irreversible remodeling.
Transition to Irreversible Remodeling Is Correlated With Accumulation of Cardiac Fibroblasts and Their Elaborated Matricellular Proteins
Cardiac fibrosis is known to be initiated and maintained by cardiac fibroblasts through collagen secretion, as well as through production of matricellular proteins regulating cellular interactions and promoting matrix organization. 21 To visualize cardiac fibroblasts, sections were immune-stained with the fibroblastspecific marker discoidin domain receptor 2 22 before and after attempted reversal. As shown in Figure 6 , the elevated discoidin domain receptor 2 levels detected in the remodeled myocardium, indicative of fibroblast accumulation, returned to baseline levels after revascularization when revascularization was exercised before the point of no return but remained high when revascularization took place at a later stage ( Figure 6A and 6B) .
Representing fibroblast-produced matricellular proteins, we examined periostin. [23] [24] [25] First, we measured periostin mRNA levels, in parallel to glucose transporter 1 (used here as a surrogate hypoxia marker) and to brain naturetic peptide (used here as a marker of general cardiac stress). Periostin was dramatically upregulated (up to 15-fold from control) from 5 weeks, ie, from the start of remodeling, and its high level of expression was maintained throughout the process ( Figure VA Glucose transporter 1 and brain naturetic peptide showed a different expression pattern, induced already at the preremodeling stage ( Figure VA in the online-only Data Supplement). Interestingly, glucose transporter 1 showed a biphasic pattern, likely reflecting an initial successful feedback response to hypoxia and a later failure to cope with further increase in vascular deficit and resultant hypoxia. These changes in hypoxia were confirmed by direct in situ staining for hypoxia with hypoxyprobe (data not shown). Brain naturetic peptide was maximally induced during the ischemic, preremodeling phase, and maintained a steady-state lower level expression (5-fold higher than control) throughout all subsequent stages.
Anticipating that reversing remodeling will be manifested by downregulation of periostin, we compared its relative level of expression after revascularization at time points representing and distinguishing reversible from irreversible remodeling. As expected, glucose transporter 1 and brain naturetic peptide returned to basal level after revascularization at both time points ( Figure VB and VC in the online-only Data Supplement). Periostin, on the other hand, while returning to base before the point of no return, failed to do so beyond this point ( Figure 6C ).
In situ mRNA hybridization was used to identify periostinexpressing cells. As shown in Figure 6A , interstitial fibroblasts but not cardiomyocytes were identified as the source of periostin. Elevated levels of periostin in the remodeled heart were also detected at the protein level, using both immunohistochemistry and Western blotting analysis ( Figure 6A and  6D) . As a secreted protein, its increased production by fibroblasts during heart remodeling is anticipated to be reflected by its increased release to the systemic circulation. Indeed, periostin was detected in mouse serum from both control and transgenic animals by Western blotting analysis. Periostin serum level was increased by ≈3-fold in the transgenic mice, and returned to control levels after revascularization ( Figure  6E and 6F ). In this regard, periostin may also serve as a useful biomarker for heart remodeling and, importantly for monitoring the efficacy of remodeling-reversing treatments.
Discussion
Adverse cardiac remodeling represents a common final pathway for many and diverse cardiac pathologies. 25 Enforced reversal of remodeling is an eminent clinical goal in prevention Figure 5 . Accumulation of collagens during progressive remodeling correlates with increased tissue inhibitor of metalloproteinase 1 (TIMP1). A, Expression levels of collagens I and III after soluble vascular endothelial growth factor receptor 1 (sVEGFR1) induction for 12 or 32 weeks were determined by real-time polymerase chain reaction (PCR). Results were normalized to littermate controls (designated as 1). n=5 to 8 mice. B and C, Collagen I protein was visualized by immunohistochemistry and quantified using sodium/iodide symporter (NIS) image analysis software. n=3 to 6 mice and 10 high-power field (HPF) were examined per each mouse. D, Expression levels of TIMP1 after sVEGFR1 induction for 12 or 32 weeks were determined by real-time PCR. Results were normalized to littermate controls (designated as 1). n=5 to 8 mice. E, Cardiac TIMP1 protein levels were determined using a TIMP1 ELISA kit (R&D) at the same time points as in (D). n=5 to 8 mice. F, TIMP1 serum protein levels were determined as in (E). n=3 to 6 mice. of heart failure. Whether remodeling, a progressively deteriorating process, is reversible at all stages of disease progression remains an unsolved issue. 9, 10 The question whether there is a point of no return in attempt to reverse remodeling is of a great clinical importance. Here we define for the first time that a point of no return indeed exists, and elucidates some of its critical characteristics.
We use a model system for conditional induction of IHD and resultant cardiac remodeling, taking advantage of the fact that in this system remodeling develops in a progressive manner at a time frame allowing dissecting the process to its individual components. This system is based on myocardium-specific induction of a VEGF-sequestering soluble receptor and a resultant well-controlled vascular deficit. Importantly, ensuing cellular hypoxia is tunable to a level at which large cohorts of cardiomyocytes are driven to enter a nonfunctional, hibernation mode 11 resulting in LV volume overload. Using this system, we show that LV dilatation, myocardial hypertrophy, and interstitial fibrosis develop in a sequential manner. We indentify the level of fibrosis as the key component to be considered in intended reversal, and show that irreversible hypertrophy is associated with an irreversible myosin isoform shift.
Therapeutic myocardial neovascularization has not yet reached the clinic despite promising preclinical studies of VEGF-driven neovascularization. 2 In fact, it is still debated whether therapeutic neovascularization is at all feasible, let alone during the end stage of IHD. Here we show that after removal of VEGF blockade, VEGF-driven neovascularization is indeed feasible even at the end stage of disease distinguished by highly fibrotic myocardium. Furthermore, regain of perfusion also rescued contractile function in cardiomyocytes that has been dysfunctional for months. Further work is needed to establish the potential of exogenous VEGF to accomplish regain of contractile function at all disease stages. Importantly, we show here that remodeling could not be reversed at the end stage even after rectifying the perfusion deficit by endogenous Figure 6 . Transition to irreversible remodeling is correlated with accumulation of cardiac fibroblasts and their elaborated matricellular proteins. A, Immunohistochemistry for discoidin domain receptor 2 (DDR2, left) and periostin (middle) in control and double-transgenic (dTg) animals after 12 weeks of vascular endothelial growth factor receptor 1 (VEGFR1) induction. In situ hybridization for periostin (right) was performed after 5 weeks of induction. In the control hearts, periostin was detected only in valve leaflet (asterisk in right upper picture), however in dTg mice, periostin was detected in the interstitial tissue (bottom). B, Quantification of DDR2 signal using ImageJ software. Control and dTg mice after 12 or 32 weeks of induction (dTg ON) and dTg mice after 12 or 32 weeks of induction and additional 3 weeks of deinduction (dTg ON>OFF). Results are standardized to littermate controls. n=3 to 6 mice and 10 high-power field (HPF) per mice. C, Expression level of periostin was determined by real-time polymerase chain reaction (PCR) for dTg mice after 12 or 32 weeks of induction (dTg ON) and for dTg mice after 12 or 32 weeks of induction and additional 3 weeks of deinduction (dTg ON>OFF), these were normalized relative to littermate controls. n=5 to 10 mice. D, Immunoprecipitation of periostin from control and dTg hearts after 5 weeks of VEGFR1 induction, subsequently submitted to Western blotting analysis (Methods). E and F, Western blotting analysis of periostin in mouse serum and quantification of results. Control and dTg mice after 5 weeks of induction (dTg ON) and dTg mice after 5 weeks of induction and additional 3 weeks of deinduction (dTg ON>OFF). Results are standardized to littermate controls. n=6. *P<0.05, **P<0.001. July 2012 VEGF-driven neovascularization. These findings, although providing further incentive for the development of proangiogenic therapy, also suggest that the timing of intended intervention is likely to be an important determinant of the clinical outcome.
What is the relevance of this model to heart remodeling and its intended reversal in the clinical setting? IHD results in a highly heterogeneous clinical spectrum, developing at different rates and severities, and affecting different myocardial regions. Correspondingly, the myocardial remodeling response to a compromised cardiac output, a common pathway on which the different conditions converge, is also likely to vary among the different conditions. Thus, remodeling patterns associated with acute myocardial infarction might be different from the process associated with chronic ischemic cardiomyopathy developing years later. Our model better represents the later, where the induced capillary rarefaction, a resultant widespread ischemia and a compromised cardiac output leads to a marked volume overload. Commonly used models of IHD-associated remodeling use a harsh, sudden insult (eg, acute myocardial infarction induced by coronary ligation). This insult results in cell death and scar formation leading to increased LV volume with a combined volume and pressure load on noninfarcted areas. 4 In contrast, in our model system progressive rarefaction culminates in increased volume overload and a slow, progressive remodeling. Thus, this model system complements currently used models, and recapitulates slowly evolving and chronic dilated ischemic cardiomyopathy. A deficit in the capillary network also exists after infarction, and it has been argued that this response of the coronary vasculature may be considered 1 of the major factors in the development of cardiomayopathy that occurs in man after myocardial infarction and in its progression into irreversible congestive heart failure. 26 Studies in other model systems have previously demonstrated the key role of angiogenesis in heart failure progression through showing that disruption of angiogenesis contributes to the transition to heart failure. 27, 28 Our study corroborates these findings, and extends them by showing that angiogenesis is, however, unable to reverse adverse remodeling at the end stage of disease.
The question arises, what are the critical cellular and molecular entities distinguishing reversible from irreversible remodeling? As a first step, we determined which subprocess in overall remodeling correlates best with transition to an irreversible state, and found it to be severe fibrosis ( Figure VI in the online-only Data Supplement). This result is in agreement with emerging clinical evidence that fibrosis impacts longterm clinical outcome in heart failure of both ischemic and nonischemic etiology. [29] [30] [31] Changes in interstitial tissue properties, primarily mediated by cardiac fibroblasts activity, 21 are the mainstay of the fibrotic process. We show that increased collagen production and decreased collagen proteolysis, the latter likely mediated by upregulated TIMP1, contribute to this process ( Figure 5 ). Further, we show that cardiac fibroblasts producing periostin, a matricellular protein involved in collagen fibrillogenesis, 32 accumulate within the interstitial tissue during remodeling, and disperse on its reversal ( Figure 6 ). Further work is required to determine the relative contribution of each of these processes for rendering myocardial remodeling irreversible.
Secreted and matricellular proteins, if accessible to the circulation, might prove useful as biomarkers for cardiac remodeling. 33, 34 In the present study, for example, we could detect both periostin and TIMP1 in the serum with the latter showing elevated levels only when remodeling was no longer reversible. Further work in this system may uncover potential biomarkers distinguishing reversible from irreversible remodeling. Once validated, such serum biomarkers may assist clinical evaluation, and improve clinical management of heart failure.
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